Despite conventional treatment options including chemoradiation, patients with the most aggressive primary brain tumor, glioblastoma multiforme (GBM), experience an average survival time of less than 15 months. Regarding the malignant nature of GBM, extensive research and discovery of novel treatments are urgently required to improve the patients’ prognosis. Autophagy, a crucial physiological pathway for the degradation and recycling of cell components, is one of the exciting targets of GBM studies. Interventions aimed at autophagy activation or inhibition have been explored as potential GBM therapeutics. This review, which delves into therapeutic techniques to block or activate autophagy in preclinical and clinical research, aims to expand our understanding of available therapies battling GBM.

尽管有包括放化疗在内的常规治疗选择，但患有最具侵袭性的原发性脑肿瘤多形性胶质母细胞瘤 (GBM) 的患者平均存活时间不到 15 个月。关于 GBM 的恶性性质，迫切需要广泛的研究和发现新的治疗方法来改善患者的预后。自噬是细胞成分降解和循环利用的重要生理途径，是 GBM 研究令人兴奋的目标之一。针对自噬激活或抑制的干预措施已被探索为潜在的 GBM 疗法。这篇综述深入研究了在临床前和临床研究中阻断或激活自噬的治疗技术，旨在扩大我们对对抗 GBM 的可用疗法的理解。